Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tesnatilimab - Janssen Biotech

Next Previous
X
Search
Drug Profile

Tesnatilimab - Janssen Biotech

Alternative Names: Anti-NKG2D; IPH-2301; IPH-23XX; JNJ 4500; JNJ-64304500; JNJ-64304500 - Janssen Biotech; NN-8555; NNC-0142-0000-0002; NNC-0142-0002

Latest Information Update: 28 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Innate Pharma; Novo Nordisk
  • Developer Janssen Biotech; Janssen Research & Development; Novo Nordisk
  • Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action NK cell lectin like receptor subfamily K antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Crohn's disease
  • Discontinued Inflammation

Most Recent Events

  • 28 Apr 2024 No recent reports of development identified for phase-I development in Crohn's-disease(In volunteers) in China (SC)
  • 25 Sep 2022 Pharmacokinetics and adverse events data from a phase IIb TRIDENT in Crohn's disease presented at the American College of Clinical Pharmacology Annual Meeting (ACCP-2022)
  • 24 Jan 2022 Janssen Research & Development completes a phase II trial in Crohn's disease in the US, France, Hungary, Germany, Japan, Russia, Poland, Ukraine, Romania, South Korea, Bulgaria, Belgium, the UK and Canada (NCT02877134)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top